Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: Randomized, phase II trial results

American Journal of Transplantation

Volumn 13, Issue 7, 2013, Pages 1746-1756

  Russ, G R ^a   Tedesco Silva, H ^b   Kuypers, D R ^c   Cohney, S ^d   Langer, R M ^e   Witzke, O ^f   Eris, J ^g   Sommerer, C ^h   Von Zur Muhlen B ⁱ   Woodle, E S ^j   Gill, J ^k   Ng, J ^l   Klupp, J ^l   Chodoff, L ^l   Budde, K ^m  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF CINCINNATI   (United States)

^k ST PAUL S HOSPITAL   (Canada)

^l NOVARTIS PHARMA AG   (Switzerland)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Efficacy; enteric coated mycophenolic acid; kidney transplantation; sotrastaurin; tacrolimus

Indexed keywords

ANTIDIABETIC AGENT; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; SOTRASTAURIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSGEUSIA; ENTERIC COATED TABLET; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEART DISEASE; HEART RATE; HUMAN; KAPOSI SARCOMA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; PHASE 2 CLINICAL TRIAL; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; VIRUS INFECTION;

BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; PYRROLES; QUINAZOLINES; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 84879551764     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12251     Document Type: Article

References (17)

1. Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: Tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol 2012; 7: 504-512.
2. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6 (5 Pt 2): 1111-1131.
3. de Mattos AM, Olyaei AJ, Bennett WM., Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346.
4. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514.
5. Olyaei AJ, de Mattos AM, Bennett WM., Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384-389.
6. Behrend M., Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001; 24: 645-663.
7. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236.
8. Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M., Gastrointestinal side effects of mycophenolic acid in renal transplant patients: A reappraisal. Nephrol Dial Transplant 2007; 22: 2440-2448.
9. Evenou JP, Wagner J, Zenke G, et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009; 330: 792-801.
10. Matz M, Naik M, Mashreghi MF, Glander P, Neumayer HH, Budde K., Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. Expert Opin Drug Metab Toxicol 2011; 7: 103-113.
11. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: First clinical results in renal-transplant recipients. Am J Transplant 2010; 10: 571-581.
12. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: Randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11: 1444-1455.
13. Kovarik JM, Steiger JU, Grinyo JM, et al. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. Transplantation 2011; 91: 317-322.
14. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
15. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS., Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
16. Hodges JL, Lehmann EL., Estimates of location based on rank tests. Ann Math Stat 1963; 34: 598-611.
17. Ekberg H, van Gelder T, Kaplan B, Bernasconi C., Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation 2011; 92: 82-87.